Back to top
more

Myriad Genetics (MYGN)

(Real Time Quote from BATS)

$18.04 USD

18.04
131,253

+0.47 (2.68%)

Updated Nov 7, 2024 11:10 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -4.41% and 12.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics (MYGN) Makes Progress in Precision Oncology

by Zacks Equity Research

Myriad Genetics' (MYGN) Precise Oncology Solutions is a wide-ranging offering intended to help oncologists determine effective and personalized treatment plans for patients.

Reasons to Hold on to Myriad Genetics (MYGN) Stock For Now

by Zacks Equity Research

Investors are optimistic about Myriad Genetics (MYGN), backed by growth in tumor profiling and GeneSight test volumes.

Myriad Genetics (MYGN) to Offer Companion Diagnostic for Lynparza

by Zacks Equity Research

Myriad Genetics' (MYGN) BRACAnalysis CDx gained FDA nod for identifying breast cancer patients eligible for treatment with Lynparza.

Myriad Genetics (MYGN) Reports Loss in Q4, Gross Margin Improves

by Zacks Equity Research

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has drove Q4 sales despite a challenging business environment.

Myriad Genetics (MYGN) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Myriad (MYGN) delivered earnings and revenue surprises of 0% and 0.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Coherus BioSciences (CHRS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 1.64% and 11.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics (MYGN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Hold on to Myriad Genetics (MYGN) for Now

by Zacks Equity Research

Investors are optimistic about Myriad Genetics (MYGN), given robust volume growth for GeneSight and prenatal testing.

Myriad Genetics (MYGN) Q3 Loss Wider Than Expected, Revenues Top

by Zacks Equity Research

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment drove Q3 sales despite a challenging business environment.

Myriad Genetics (MYGN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myriad (MYGN) delivered earnings and revenue surprises of -300.00% and 1.80%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain LabCorp (LH) Stock For Now

by Zacks Equity Research

Strength in Drug Development business and new strategies to expand into high-growth markets raise optimism for LabCorp (LH).

Here's Why You Should Retain Myriad Genetics (MYGN) for Now

by Zacks Equity Research

Investors are optimistic about Myriad Genetics (MYGN) owing to strong testing volume growth and notable product launches.

LabCorp (LH) Gets FDA's EUA for Combined Home Collection Kit

by Zacks Equity Research

The EUA for LabCorp's (LH) combined home collection kit can enable health-care providers to identify and treat individuals suspected of COVID-19 or influenza A/B infection.

LabCorp (LH) Bolsters RA Testing by Adding Myriad's Vectra

by Zacks Equity Research

According to LabCorp (LH), Vectra and the related IP and other assets from Myriad Genetics' autoimmune business complement its prior business activity.

Illumina (ILMN), Merck Ink Cancer Companion Diagnostics Deal

by Zacks Equity Research

Illumina (ILMN) collaborated with Merck to develop and commercialize companion diagnostics to identify ovarian cancer patients with positive HRD status for treatment with LYNPARZA.

Agilent (A) Boosts PD-L1 IHC 22C3 pharmDX Assay Use in Europe

by Zacks Equity Research

Agilent Technologies (A) boosts presence in the companion diagnostics market by expanding the use of PD-L1 IHC 22C3 pharmDx assay for esophageal cancer treatment in Europe.

Myriad Genetics (MYGN) Q2 Earnings Beat, Gross Margin Rises

by Zacks Equity Research

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q2 sales despite a challenging business environment.

Myriad Genetics (MYGN) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Myriad (MYGN) delivered earnings and revenue surprises of 271.43% and 13.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics (MYGN) Divests Myriad RBM to Focus on Core Units

by Zacks Equity Research

Myriad Genetics' (MYGN) new divesture will enable company to accelerate the execution of transformation plan and drive growth.

Why Is Myriad (MYGN) Down 11.5% Since Last Earnings Report?

by Zacks Equity Research

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Myriad Genetics (MYGN) Sells myPath to Focus on Core Units

by Zacks Equity Research

Myriad Genetics' (MYGN) new divesture will provide the company with growth capital for future investments.

Myriad Genetics' (MYGN) GeneSight Test Rollout Initiated by IPM

by Zacks Equity Research

Myriad Genetics' (MYGN) GeneSight testing distribution initiated through IPM will help clinicians and patients assess individual's response to certain medications.

Hologic (HOLX) ThinPrep Genesis Processor Gets FDA Approval

by Zacks Equity Research

Hologic's (HOLX) ThinPrep Genesis processor offers new automation capabilities and workflow enhancements.

Myriad Genetics (MYGN) Beats on Q1 Earnings and Revenues

by Zacks Equity Research

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q1 sales despite pandemic-led business challenges.